Associate Director
REGENXBIO
Associate Director
REGENXBIO
Develops AAV gene delivery therapies
As the Associate Director, Rare Disease Product Marketing, you’ll serve as an insights-driven brand marketer and strategic partner to Commercial, Portfolio, and cross-functional teams. Through this work, you’ll shape and execute product marketing strategy, customer engagement, and launch readiness. You’ll develop integrated brand plans, positioning, messaging, and promotional initiatives for HCP, payer, caregiver, and field audiences. Bringing together market research and field feedback to inform decisions, you will balance strategic planning with hands-on execution across the product lifecycle.
We set our employees up for success. To be successful in this role and help us achieve our goals, we are looking for someone with the following skills and qualifications:
By joining REGENXBIO, you will have the opportunity to be a part of a growing company, with an incredible team, who is passionate about developing novel AAV gene therapies for patients in need.
We offer a comprehensive and competitive benefit & compensation package which includes market-competitive salaries, an annual bonus program, education assistance, retirement plan with employer match, stock options at all levels, summer hours and more! The estimated compensation range for this role is $160,000 to $215,000 annually. The actual salary offered to the final candidate depends on a number of factors such as relevant work experience, skills, education, and years of experience.
In addition, professional development is important to us. By joining our team, you’ll have the opportunity to be exposed to challenging projects and have access to development resources to help you grow personally and professionally.
REGENXBIO focuses on gene therapy using its NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system with exclusive rights to more than 100 AAV vectors. The company generates revenue by licensing its platform, collecting royalties, and engaging in collaborations, while also developing its own one-time gene therapies for retinal, rare, and neurodegenerative diseases. Key products in later-stage trials include ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Hunter syndrome, with a goal to advance five new therapies to pivotal-stage or commercial status by 2025 and FDA review for RGX-121 targeted in early 2026. REGENXBIO differentiates itself by owning a broad AAV vector library and offering end-to-end capabilities—from research to manufacturing—alongside a diversified revenue model that includes royalties, collaborations, and milestones.
Explore more opportunities at REGENXBIO